USPTO

AbbVie Humira Patent Thicket Delays US Biosimilars Until 2023 Despite 2016 Patent Expiration and European Competition

2018-10-16 00:00:00 +0000 UTC | Importance: 9/10

AbbVie reached settlement agreements with eight biosimilar manufacturers that allowed immediate biosimilar competition in Europe starting October 16, 2018, but delayed all US market entry until 2023—seven years after Humira’s original patent expired in December 2016. The settlements ended …

AbbVie Amgen Samsung Bioepis Mylan Boehringer Ingelheim +3 more pharmaceutical-industry patent-abuse drug-pricing healthcare evergreening +2 more

Alice Corp. v. CLS Bank: Supreme Court Restricts Software Patents, Reducing Patent Troll Leverage Over Abstract Business Methods

2014-06-19 00:00:00 +0000 UTC | Importance: 8/10

The Supreme Court unanimously rules in Alice Corp. v. CLS Bank International (573 U.S. 208) that abstract ideas implemented on generic computers are not patent-eligible under 35 U.S.C. § 101, establishing a two-step framework for patent eligibility. Justice Thomas delivers the opinion holding that …

Supreme Court Clarence Thomas Alice Corp CLS Bank International USPTO intellectual-property patent-abuse software-patents supreme-court business-methods +1 more